Sources

The source registry

Every load-bearing claim on this site traces to one of the primary sources below. Secondary coverage is used for discovery, never as the citation of record.

Regulatory

FDA press announcement, April 30, 2026 — proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. Federal Register notice, May 1, 2026: 91 Fed. Reg. 23431, with the comment period extended and closed July 30, 2026. FDA drug-shortage database entries — tirzepatide resolution (December 2024) and the 503B wind-down timeline to March 19, 2025. FDA compounding framework, Sections 503A/503B of the FD&C Act. The June 2026 FDA warning letter to AltRx's parent company regarding website claims.

Clinical

Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022. SURMOUNT-5 head-to-head results, tirzepatide versus semaglutide, 2025. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021. The SELECT cardiovascular-outcomes results for semaglutide. Zepbound and Wegovy prescribing information for titration schedules and label warnings.

Price primaries

NexLife's six published plan pages (Standard, Microdose and Sublingual protocols, both molecules) — the audited set, figures confirmed August 14, 2026. Published pricing pages of Hims, Hers, Henry Meds, Mochi Health, ShedRx, Remedy Meds, AltRx (primary domain only), Fifty 410, Eden, Found, Noom Med, Ro. Brand reference pricing: LillyDirect single-dose Zepbound vials; NovoCare Wegovy self-pay; Zepbound list pricing. Every figure's exact source URL is filed row-by-row in the dataset.

Sourcing policy: primary documents over coverage of documents; dated claims carry their dates in the text; when a source and our audit disagree, the audit note says so publicly. Errors: the corrections desk.